Evidence map›Paper›PMID 33923275›Full record

ReviewLife (Basel, Switzerland)2021

Dynamic Interplay between Copper Toxicity and Mitochondrial Dysfunction in Alzheimer's Disease.

Giusy Tassone, Arian Kola, Daniela Valensin, Cecilia Pozzi

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Copper homeostasis and cuproptosis in Alzheimer's disease (Review).International journal of molecular medicine · 2025
    Review
  3. Application of Modulators of CaInternational journal of molecular sciences · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Dysfunctional copper homeostasis inRedox biochemistry and chemistry · 2024
    Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Giusy TassoneDepartment of Biotechnology, Chemistry and Pharmacy-Department of Excellence 2018-2020, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID 0000-0002-2575-5528
Arian KolaDepartment of Biotechnology, Chemistry and Pharmacy-Department of Excellence 2018-2020, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Daniela ValensinDepartment of Biotechnology, Chemistry and Pharmacy-Department of Excellence 2018-2020, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Cecilia PozziDepartment of Biotechnology, Chemistry and Pharmacy-Department of Excellence 2018-2020, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID 0000-0003-2574-3911
University of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder, affecting millions of people worldwide, a number expected to exponentially increase in the future since no effective treatments are available so far. AD is characterized by severe cognitive dysfunctions associated with neuronal loss and connection disruption, mainly occurring in specific brain areas such as the hippocampus, cerebral cortex, and amygdala, compromising memory, language, reasoning, and social behavior. Proteomics and redox proteomics are powerful techniques used to identify altered proteins and pathways in AD, providing relevant insights on cellular pathways altered in the disease and defining novel targets exploitable for drug development. Here, we review the main results achieved by both -omics techniques, focusing on the changes occurring in AD mitochondria under oxidative stress and upon copper exposure. Relevant information arises by the comparative analysis of these results, evidencing alterations of common mitochondrial proteins, metabolic cycles, and cascades. Our analysis leads to three shared mitochondrial proteins, playing key roles in metabolism, ATP generation, oxidative stress, and apoptosis. Their potential as targets for development of innovative AD treatments is thus suggested. Despite the relevant efforts, no effective drugs against AD have been reported so far; nonetheless, various compounds targeting mitochondria have been proposed and investigated, reporting promising results.

Indexed as

Alzheimer diseasecoppermitochondriaoxidative stressproteomicsredox proteomics

Identifiers

PMID33923275
PMCPMC8146034
OpenAlexW3158213304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.